Steven Jon Russell Sells 1,039 Shares of Beta Bionics, Inc. (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Steven Jon Russell sold 1,039 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $18,587.71. Following the completion of the sale, the insider now directly owns 72,032 shares in the company, valued at approximately $1,288,652.48. The trade was a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Beta Bionics Price Performance

BBNX traded down $0.47 on Friday, reaching $19.08. The company had a trading volume of 583,609 shares, compared to its average volume of 503,190. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $24.50. The stock's 50-day simple moving average is $13.05.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.01).

Institutional Investors Weigh In On Beta Bionics

Hedge funds have recently made changes to their positions in the business. Driehaus Capital Management LLC acquired a new stake in shares of Beta Bionics during the first quarter worth about $10,799,000. Ghisallo Capital Management LLC acquired a new stake in shares of Beta Bionics during the first quarter worth about $612,000. Omega Fund Management LLC acquired a new stake in shares of Beta Bionics during the first quarter worth about $24,337,000. Walleye Capital LLC acquired a new stake in shares of Beta Bionics during the first quarter worth about $1,813,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Beta Bionics during the first quarter worth about $47,346,000.

Analyst Upgrades and Downgrades

BBNX has been the topic of a number of research analyst reports. Robert W. Baird initiated coverage on Beta Bionics in a research report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 target price on the stock. Leerink Partners began coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued an "outperform" rating and a $28.00 price target for the company. Bank of America began coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating for the company. Baird R W upgraded shares of Beta Bionics to a "hold" rating in a research note on Thursday, February 20th. Finally, Leerink Partnrs upgraded shares of Beta Bionics to a "strong-buy" rating in a research note on Monday, February 24th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $23.13.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.